Genomic Profile of Interleukin-6 Secreting Ovarian Cancer: Validation of Future Biomarkers and Target of Therapy.
文献摘要
Background Inflammation is one of the main events in ovarian cancer pathogenesis. Ovarian cancer secreting interleukin-6 (IL-6) as a pro-inflammatory cytokine can have altered genetic profiles that contribute to the progression of the disease. The lack of integrative studies combining quantitative IL-6 measurement with genomic profiling in ovarian cancer has not been further assessed. Therefore, this study aimed to explore genomic profile of ovarian cancer using the most current sequencing method to identify fundamental alterations in the pathobiology. Genomic profiles further may provide candidate biomarkers for future validation. Methods A total of 45 subjects were recruited and received surgery for indications of an ovarian tumor. Among these subjects, 18 were diagnosed as malignant disease, 19 were considered benign and 8 as borderline ovarian cancer. IL-6 level was measured from both serum and intratumoral with ELISA. Ovarian cancer with a high secretion level of IL-6 received deep whole-genome sequencing performed with ONT. Results The results showed that the secretion level of IL-6 was consistent in serum and intratumoral fluid. In addition, patients with malignancy showed significant secretion of IL-6 compared to benign disease (p = 0.027), according to systemic inflammation markers (NLR, PLR, and SII). Based on sequencing, IL-6-secreting ovarian cancer showed alteration of genes for MTRF1, IL-10, IL-6, APC, PAX8, PTGS2, and PACERR. Conclusion Ovarian malignancy has a significant secretion of pro-inflammatory cytokines. Additionally, the inflammatory condition contributes to the disruption of genetic landscapes in the ovarian cancer pathogenesis. As an exploratory cross-sectional analysis, these findings identify potential associations and candidate genomic features involved in ovarian cancer pathogenesis, diagnosis and treatment strategies.